# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Hartaj Singh maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target fr...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.
Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive di...
Significant Reduction in Dehydroepiandrosterone Sulfate (DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels a...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.
Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(...
Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compl...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow...